Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759726 | 1.00 | CHRM1 (0.32) | CHRM1PDGFRAHRH3PDCD1CD274 | |
| SCHEMBL29759961 | 0.87 | IRAK4 (0.34) | CHRM1PDGFRAHRH3IRAK4 | |
| SCHEMBL27184975 | 0.87 | IRAK4 (0.34) | CHRM1PDGFRAHRH3IRAK4 | |
| SCHEMBL29759648 | 0.87 | WNT1 (0.37) | CHRM1PDGFRAHRH3OGAIRAK4 | |
| SCHEMBL24577265 | 0.87 | WNT1 (0.37) | CHRM1PDGFRAHRH3OGAIRAK4 | |
| SCHEMBL29760042 | 0.86 | PDCD1 (0.33) | CHRM1PDGFRAHRH3PDCD1CD274 | |
| SCHEMBL27185330 | 0.86 | PDCD1 (0.33) | CHRM1PDGFRAHRH3PDCD1CD274 | |
| SCHEMBL27185031 | 0.85 | POLQ (0.34) | CHRM1PDGFRAHRH3 | |
| SCHEMBL24578461 | 0.85 | ALDH1A1 (0.40) | — | |
| SCHEMBL24579109 | 0.85 | ALDH1A1 (0.39) | CHRM1PDGFRAHRH3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | CHRM1 4399/4885PDGFRA 1/4885HRH3 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.